Notably this study included only wild‐type EGFR cell lines and did not specifically evaluate EGFR mutant patients, so further studies are needed to elucidate the interactions between DRD1 and EGFR and investigate the potential utility of targeting DRD1 in EGFR mutant NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.